This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / Zynex Faces Securities Class Action
Regulatory class action

Zynex Faces Securities Class Action

Analysis based on 10 articles · First reported Mar 26, 2025 · Last updated Apr 17, 2025

Sentiment
-70
Attention
4
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Zynex, coupled with the suspension of payments from United States — Tricare and a significant revenue shortfall, has led to a drastic decline in Zynex's stock price. This event highlights the risks associated with alleged fraudulent business practices and their severe financial consequences for publicly traded companies and their investors.

Medical Devices Healthcare
Event Summary

Zynex, a publicly traded company, is facing a federal securities class action lawsuit filed by Faruqi & Faruqi. The lawsuit alleges that Zynex engaged in an 'oversupplying scheme' by shipping excessive products, including electrodes, to inflate its revenue. This practice led to Zynex filing false claims, which drew scrutiny from insurers like United States — Tricare. A report by Stat (website) on June 4, 2024, detailed this scheme, causing Zynex's stock price to fall by 5%. Further, on March 11, 2025, Zynex reported a significant revenue shortfall for Q4 and full year 2024, attributing it to slower payments from certain payers and revealing that United States — Tricare had temporarily suspended payments to review prior claims. This news caused Zynex's stock price to plummet by over 51%. Faruqi & Faruqi, through partner James Wilson, is encouraging investors who suffered losses to join the class action lawsuit, with a lead plaintiff deadline of May 19, 2025.

Key Actions
100 Faruqi & Faruqi filed class action lawsuit Zynex
95 Zynex reported revenue shortfall
95 United States — Tricare suspended payments Zynex
90 Zynex shipped products in excess
90 Zynex inflated revenue
85 Zynex filed false claims
70 Stat (website) published report Zynex
Entities Involved
stock
Zynex
Zynex is facing a class action lawsuit for allegedly inflating revenue through an 'oversupplying scheme' and making false statements, leading to significant stock price drops and suspension of payments from United States — Tricare.
Importance 100.0 Sentiment -80.0
govactor
United States — Tricare
United States — Tricare, the health insurance program for the U.S. military, temporarily suspended payments to Zynex as they review prior claims, indicating scrutiny of Zynex's billing practices.
Importance 60.0 Sentiment 0.0
oth
Stat (website)
STAT, a medical journal, published a report on Zynex's 'oversupplying scheme,' which contributed to the initial drop in Zynex's stock price.
Importance 40.0 Sentiment 0.0
priv
Faruqi & Faruqi
Importance 0.0 Sentiment 0.0
per
James Wilson
Importance 0.0 Sentiment 0.0
Relationships
Zynex investigated provider ↔ United States — Tricare Zynex is a medical device provider that bills the US government's Tricare program. The relationship is currently adversa
Faruqi & Faruqi related ↔ James Wilson
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.